2. NF-κB
  3. NF-κB
  4. JSH-23

JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.

For research use only. We do not sell to patients.

JSH-23 Chemical Structure

JSH-23 Chemical Structure

CAS No. : 749886-87-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 117 In-stock
Solution
10 mM * 1 mL in DMSO USD 117 In-stock
Solid
5 mg USD 106 In-stock
10 mg USD 150 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 99 publication(s) in Google Scholar

JSH-23 Related Antibodies

Top Publications Citing Use of Products

92 Publications Citing Use of MCE JSH-23

WB
RT-PCR

    JSH-23 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Apr 14;42(4):112403.  [Abstract]

    JSH-23 (10 μM; 6 days) significantly inhibits nuclear translocation of NF-kB p65 in SSC cells.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Front Bioeng Biotechnol. 2020 May 8;8:392.  [Abstract]

    Acta2 expression after Signaling inhibitors by q-PCR. For inhibitor treatment, 24 h after seeding, the medium is removed and replaced with the NF-κB inhibitor JSH-23 (50 μM) to block the NF-κB signaling pathways.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 1;428:77-89.  [Abstract]

    Western blots show that the NF-κB inhibitors BAY11-7082, Parthenolide, and JSH-23 cause dramatic time- and dose-dependent reductions in MGMT protein expression in LN18 and T98G glioma cells.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21;9:660.  [Abstract]

    By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

    JSH-23 purchased from MedChemExpress. Usage Cited in: J Mol Cell Biol. 2019 Jun 1;11(6):496-508.  [Abstract]

    Cytoplasmic LPS-induced GSDMB and GSDMD expression are both significantly attenuated by either JSH-23 or QNZ.

    JSH-23 purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2017;10(6):6544-6551.

    JSH-23 is added into MDA-MB-231 cells with the dose of 0 μmol, 1 μmol, 5 μmol when the cell planking density reaches about 60%. Then samples incubated for 24 h are collected when the cell density reaches about 80% and confirmed by western blot.

    JSH-23 purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Nov 16;11(11):e0166740.  [Abstract]

    HG-induced apoptosis in neonatal rat cardiomyocytes is mediated by activation of the NF-κB pathway. (A-B). Neonatal rat cardiomyocytes are pretreated with 10–20 μM JSH-23 and exposed to HG for 36 h. Levels of caspase-3 and cleaved caspase-3 and Bax/Bcl-2 ratios are determined by western blotting.

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation[1].

    IC50 & Target[1]

    NF-κB

    7.1 μM (IC50, in RAW 264.7 cells)

    In Vitro

    JSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells[1].
    Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    JSH-23 Related Antibodies

    Cell Cytotoxicity Assay[1]

    Cell Line: Macrophages RAW 264.7
    Concentration: 1, 3, 10, 30, 100, 300 μM
    Incubation Time: 24 hours
    Result: Did not show significant cytotoxic effects at <100 μM.

    Western Blot Analysis[1]

    Cell Line: Macrophages RAW 264.7 with LPS-stimulated
    Concentration: 30 μM
    Incubation Time: 1 hour
    Result: Decreased nuclear content of NF-κB p65 in a dose-dependent manner, corresponding to 49±4% inhibition at 3 μM, 75±7% at 10 μM and 95±8% at 30 μM.
    In Vivo

    JSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague Dawley diabetic rats (250-270 g)[2]
    Dosage: 1 mg/kg, 3 mg/kg
    Administration: Orally administered; daily; for 2 weeks
    Result: Produced significant improvement in motor nerve conduction velocity (MNCV).
    Molecular Weight

    240.34

    Formula

    C16H20N2
    CAS No.
    Appearance

    Solid

    Color

    Purple to reddish brown

    SMILES

    NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 56 mg/mL (233.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1608 mL 20.8039 mL 41.6077 mL
    5 mM 0.8322 mL 4.1608 mL 8.3215 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.40 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (10.40 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    SDS (620 KB)

    COA (244 KB) LCMS (93 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.1608 mL 20.8039 mL 41.6077 mL 104.0193 mL
    5 mM 0.8322 mL 4.1608 mL 8.3215 mL 20.8039 mL
    10 mM 0.4161 mL 2.0804 mL 4.1608 mL 10.4019 mL
    15 mM 0.2774 mL 1.3869 mL 2.7738 mL 6.9346 mL
    20 mM 0.2080 mL 1.0402 mL 2.0804 mL 5.2010 mL
    25 mM 0.1664 mL 0.8322 mL 1.6643 mL 4.1608 mL
    30 mM 0.1387 mL 0.6935 mL 1.3869 mL 3.4673 mL
    40 mM 0.1040 mL 0.5201 mL 1.0402 mL 2.6005 mL
    50 mM 0.0832 mL 0.4161 mL 0.8322 mL 2.0804 mL
    60 mM 0.0693 mL 0.3467 mL 0.6935 mL 1.7337 mL
    80 mM 0.0520 mL 0.2600 mL 0.5201 mL 1.3002 mL
    100 mM 0.0416 mL 0.2080 mL 0.4161 mL 1.0402 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    JSH-23 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    JSH-23749886-87-1JSH23JSH 23NF-κBNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    JSH-23
    Cat. No.:
    HY-13982
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (620 KB) Français - FR (620 KB) Deutsch - DE (620 KB) Norwegian - NO (620 KB) Español - ES (620 KB) Swedish - SV (620 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.